Alimera Sciences (FRA:ASZ1) EV-to-Revenue : 2.97 (As of May. 11, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alimera Sciences's enterprise value is €222.13 Mil. Alimera Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €74.86 Mil. Therefore, Alimera Sciences's EV-to-Revenue for today is 2.97.

The historical rank and industry rank for Alimera Sciences's EV-to-Revenue or its related term are showing as below:

FRA:ASZ1' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9 Med: 3.18 Max: 931.8
Current: 2.97

During the past 13 years, the highest EV-to-Revenue of Alimera Sciences was 931.80. The lowest was 0.90. And the median was 3.18.

FRA:ASZ1's EV-to-Revenue is ranked worse than
56.77% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.41 vs FRA:ASZ1: 2.97

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-11), Alimera Sciences's stock price is €3.225. Alimera Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €4.94. Therefore, Alimera Sciences's PS Ratio for today is 0.65.

Alimera Sciences EV-to-Revenue Historical Data

The historical data trend for Alimera Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences EV-to-Revenue Chart

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1.82

1.51

1.39

1.44

3.46

Alimera Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.44	0.98	2.48	3.19	3.46

Competitive Comparison of Alimera Sciences's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alimera Sciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's EV-to-Revenue falls into.

Alimera Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Alimera Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	222.125	/	74.855
	=	2.97

Alimera Sciences's current Enterprise Value is €222.13 Mil.
Alimera Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €74.86 Mil.

Alimera Sciences (FRA:ASZ1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Alimera Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.225	/	4.942
	=	0.65

Alimera Sciences's share price for today is €3.225.
Alimera Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.94.

Alimera Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (FRA:ASZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (FRA:ASZ1) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ALIM:USA

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (FRA:ASZ1) Headlines

No Headlines